outcome of Board MeetinO
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals' board, meeting on 16 October 2025, approved several key items. CA Yash Jain was appointed as Internal Auditor for FY 2025-26, Mr. Yogesh Supekar (MBA Finance, 24 years' experience in banking and finance media) joined as an Additional Non-Executive Director, and Mr. Rishi Upadhaya was appointed as Company Secretary and Compliance Officer. The board also approved raising up to ₹3 crore as an interest-free unsecured loan from its existing directors, to be drawn in lump sum or tranches. Additionally, a loan facility of up to ₹2.70 crore from HDFC Bank was sanctioned, secured against a commercial property the company plans to purchase.
The director-funded interest-free loan of ₹3 crore signals promoter confidence and provides low-cost working capital support, while the HDFC Bank loan indicates an upcoming real estate/commercial space acquisition. New governance appointments strengthen the company's compliance and financial oversight structure.